These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12855664)

  • 1. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
    Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
    Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
    Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
    Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
    Debinski W; Pastan I
    Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
    Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
    Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
    Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
    Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
    Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
    Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
    Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
    Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
    Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
    Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
    Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
    Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
    Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a modular immunotoxin connected by polyionic adapter peptides.
    Kleinschmidt M; Rudolph R; Lilie H
    J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cell surface antigens as potential targets for recombinant tumor toxins.
    Wick B; Groner B
    Cancer Lett; 1997 Oct; 118(2):161-72. PubMed ID: 9459206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
    Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
    Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.